SlideShare a Scribd company logo
107. Proposal of a tool for the assessment of the quality of
Gaucher disease clinical management.
*Giner V1
, Fernández MA2
, Villarrubia J3
, Bureo JC4
, Fernández JJ5
, Núñez R6
, Grande M7
, Llorente C7
, Zoni AC8
, Arenas CA9
, Vicente D1
, Sanz J1
.
1
Rare Diseases Unit. Department of General Internal Medicine. Hospital Mare de Déu dels Lliris. Alcoy. Spain. 2
Department of Hematology. Hospital Virgen del Puerto. Plasencia (Cáceres).Spain. 3
Department of Hematology. Hospital
Universitario Ramón y Cajal. Madrid. Spain. 4
Department of General Internal Medicine. Hospital Infanta Cristina. Badajoz. Spain. 5
Department of General Internal Medicine. Hospital do Meixoeiro. Vigo. Spain. 6
Unit of Hemophilia.
Department of Hematology. Hospital Universitario Virgen del Rocío. Sevilla. Spain. 7
Department of Preventive Medicine and Quality of Care. Hospital General Universitario Gregorio Marañón. SERMAS. Madrid. Spain. 8
Epidemiology Area.
Subdirection for Health Promotion and Prevention. Consejería de Salud de la Comunidad de Madrid. Madrid. Spain. 9
Sociedad Española de Directivos de Salud (SEDISA).
*Presenting and corresponding author: giner_vicgal@gva.es
IntroductionIntroduction
MethodologyMethodology
Internal Medicine
Department
Rare Diseases Unit
Alcoi (Alicante).
Spain.
To avoid unjustified clinical variation in the way we manage our patinets and to assure it is being
done in the best way, it is necessary tools for the evaluation of the quality of our work. It is specially
noteworthy in rare diseases due to the scarce amount of clear and definite evidence we have.
To create a tool for the evalution of the assistance given to GD patients as the first
step to improve our assisstance.
Phase 1
Objetive:
Identification and analysis of existing publications about quality in GD management.
Methodology:
Review of the published evidence in Medline (PubMed)©
, Embase©
and Cochrane©
databases according to PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) methodology until october 2013.
Phase 2
Objetive:
First proposal of quality criteria for 3 clinical scenarios: Diagnosis, Treatment and Follow-up.
Methodology:
Creation of an expert group with seven national experts on GD.
Initial proposal for quality criteria after evaluation and adaptation to spanish clinical practice.
As illustrated in Figure 1, the project was developed in four consecutive phases between 2013 and 2016:
Phase 3
Objetive:
General consensus for the election of significant quality indicators.
Methodology:
Identification of national physicians with expertise in the management of GD.
Consensuated evaluation of proposed quality criteria by 31 national treating GD
patients in two Delphi rounds. In each round the panelists evaluated each proposal
applying a 9 points Likert scale.
Phase 4
Objetive:
Final manuscript for clinical aplication.
Methodology:
Creation of a work sheet for each quality indicator according to Sociedad Española de
Calidad Asistencial (SECA) (Spanish Society of Assitential Quality) 2012 protocol for the Spanish
Public Health System hospitals.
ResultsResults
Phase 1 Phase 2 Phase 3 Phase 4
ScenarioScenario Quality parameterQuality parameter CalculationCalculation ObjectiveObjective
Diagnosis (D)
D1. Anamnesis and physical exploration GD patients with D1/All GD patients x 100 100%
D2. Basic general analytical study GD patients with D2/All GD patients x 100 100%
D3. Glucocerebrosidase activity GD patients with D3/All GD patients x 100 100%
D4. Genetic study GD patients with D4/All GD patients x 100 100%
D5. Biomarkers GD patients with D5/All GD patients x 100 100%
D6. Bone disease evaluation GD patients with D6/All GD patients x 100 100%
D7. Organomegaly evaluation GD patients with D7/All GD patients x 100 100%
D8. Global severity evaluation GD patients with D8/All GD patients x 100 100%
D9. Exhaustive familial story GD patients with D9/All GD patients x 100 100%
D10. Familial screening GD patients with D10/All GD patients x 100 100%
Treatment (T)ERT: Enzyme replacement Therapy
SRT: Substracte reduction Therapy
T1. Specific treatment: ERT GD patients with T1/All GD patients x 100
T1.1 and T1.2 100%,
T1.3 50%, T1.4 0%
T2. Specific treatment: SRT GD patients with T2/All GD patients x 100 100%
T3. Therap. objective: Anemia GD patients with T3/All GD patients x 100 100%
T4. Therap. objective: Thrombopenia GD patients with T4/All GD patients x 100 T4.1, T4.2, T4.3, T4.4, T4.5 100%
T5. Therap. objective: Hepatomegaly GD patients with T5/All GD patients x 100 T5.1 ≥20 %, T5.2 ≥30 %.
T6. Therap. objective: Splenomegaly GD patients with T6/All GD patients x 100 T6.1 ≥30 %, T6.2 ≥60 %.
T7. Therap. objective: Bone GD patients with T7/All GD patients x 100 T7.1 ≥20%, T7.2 ≥50%, T7.3 ≥30%.
Follow-up (F)
F1. Continuos and planned follow-up GD patients with T7/All GD patients x 100 F1.1, F1.2, F1.3 100%
F2. No reached objectives GD patients with T7/All GD patients x 100 100%
ConclusionsConclusions
Figure 1. Methodological
phases in the confection
of the final document
entitled “Guía práctica de
indicadores de calidad
asistencial en la
enfermedad de Gaucher”
(“Practical guideline of
assistential quality
indicators in Gaucher
disease”).
This project has been supported
by Shire Pharmaceuticals Iberica©
ObjectiveObjective
Although the process of quality is essential to improve
health care, the presented is the only reported specific
tool to assess quality of actual GD clinical management.
Because of very scarce bibliographic evidence and
high level of consensuated decisions, probably a
specific document for each Health system is necessary.
The simplicity of the proposed system could facilitate its
application as a way to improve and standarize clinical
management of GD patients as a continuous
improvement process.

More Related Content

What's hot

Posters wonca2013
Posters wonca2013Posters wonca2013
Posters wonca2013
agunin69
 
PROs and Patient Preference Studies
PROs and Patient Preference StudiesPROs and Patient Preference Studies
PROs and Patient Preference Studies
Sheily Kamra
 
1_21_Epiona Clinical Study 62460 RN
1_21_Epiona Clinical Study 62460 RN1_21_Epiona Clinical Study 62460 RN
1_21_Epiona Clinical Study 62460 RN
Sally Dixon
 
Methodology Atlas nº6. Atlas of variations in oncologic surgery hopitalisations
Methodology Atlas nº6. Atlas of variations in oncologic surgery hopitalisationsMethodology Atlas nº6. Atlas of variations in oncologic surgery hopitalisations
Methodology Atlas nº6. Atlas of variations in oncologic surgery hopitalisations
Atlas VPM
 
Les 2019
Les  2019Les  2019
Les 2019
Bruce2401
 
Mpv msv final
Mpv msv  finalMpv msv  final
Mpv msv final
Neha Sharma
 
The utility of “blind” 131I treatments for differentiated thyroid cancer: an...
The utility of “blind” 131I treatments for differentiated thyroid cancer:  an...The utility of “blind” 131I treatments for differentiated thyroid cancer:  an...
The utility of “blind” 131I treatments for differentiated thyroid cancer: an...
Michael
 
How to read a forest plot?
How to read a forest plot?How to read a forest plot?
How to read a forest plot?
Samir Haffar
 
Chapter 25 assessment of clincal responses
Chapter 25 assessment of clincal responsesChapter 25 assessment of clincal responses
Chapter 25 assessment of clincal responses
Nilesh Kucha
 
S0039610907001752
S0039610907001752S0039610907001752
S0039610907001752
guidoencarnacion
 
Practice parameters for_the_treatment_of_sigmoid.
Practice parameters for_the_treatment_of_sigmoid.Practice parameters for_the_treatment_of_sigmoid.
Practice parameters for_the_treatment_of_sigmoid.
Silvina Verna
 
Sensitivity and specificity
Sensitivity and specificitySensitivity and specificity
Sensitivity and specificity
messi1910
 
Ct lecture 20. survival analysis (part 2)
Ct lecture 20. survival analysis (part 2)Ct lecture 20. survival analysis (part 2)
Ct lecture 20. survival analysis (part 2)
Hau Pham
 
Screening and diagnostic tests
Screening and diagnostic testsScreening and diagnostic tests
Screening and diagnostic tests
Bharat Paul
 
PMartinez - Literature Review
PMartinez - Literature ReviewPMartinez - Literature Review
PMartinez - Literature Review
Priscilla Martinez
 
Journal club-Determination of surgical priorities in appendicitis
Journal club-Determination of surgical priorities in appendicitisJournal club-Determination of surgical priorities in appendicitis
Journal club-Determination of surgical priorities in appendicitis
Youttam Laudari
 
What is survival analysis, and when should I use it?
What is survival analysis, and when should I use it?What is survival analysis, and when should I use it?
What is survival analysis, and when should I use it?
Cecilia M. Patino-Sutton, MD MeD PhD
 
Jc
JcJc
The values of clinical practice - Jordi Varela
The values of clinical practice - Jordi VarelaThe values of clinical practice - Jordi Varela
The values of clinical practice - Jordi Varela
Jordi Varela
 
Research on ADR in in-patients using Naronji's and who scale: A basic necessi...
Research on ADR in in-patients using Naronji's and who scale: A basic necessi...Research on ADR in in-patients using Naronji's and who scale: A basic necessi...
Research on ADR in in-patients using Naronji's and who scale: A basic necessi...
ANURAG GROUP OF INSTITUTIONS
 

What's hot (20)

Posters wonca2013
Posters wonca2013Posters wonca2013
Posters wonca2013
 
PROs and Patient Preference Studies
PROs and Patient Preference StudiesPROs and Patient Preference Studies
PROs and Patient Preference Studies
 
1_21_Epiona Clinical Study 62460 RN
1_21_Epiona Clinical Study 62460 RN1_21_Epiona Clinical Study 62460 RN
1_21_Epiona Clinical Study 62460 RN
 
Methodology Atlas nº6. Atlas of variations in oncologic surgery hopitalisations
Methodology Atlas nº6. Atlas of variations in oncologic surgery hopitalisationsMethodology Atlas nº6. Atlas of variations in oncologic surgery hopitalisations
Methodology Atlas nº6. Atlas of variations in oncologic surgery hopitalisations
 
Les 2019
Les  2019Les  2019
Les 2019
 
Mpv msv final
Mpv msv  finalMpv msv  final
Mpv msv final
 
The utility of “blind” 131I treatments for differentiated thyroid cancer: an...
The utility of “blind” 131I treatments for differentiated thyroid cancer:  an...The utility of “blind” 131I treatments for differentiated thyroid cancer:  an...
The utility of “blind” 131I treatments for differentiated thyroid cancer: an...
 
How to read a forest plot?
How to read a forest plot?How to read a forest plot?
How to read a forest plot?
 
Chapter 25 assessment of clincal responses
Chapter 25 assessment of clincal responsesChapter 25 assessment of clincal responses
Chapter 25 assessment of clincal responses
 
S0039610907001752
S0039610907001752S0039610907001752
S0039610907001752
 
Practice parameters for_the_treatment_of_sigmoid.
Practice parameters for_the_treatment_of_sigmoid.Practice parameters for_the_treatment_of_sigmoid.
Practice parameters for_the_treatment_of_sigmoid.
 
Sensitivity and specificity
Sensitivity and specificitySensitivity and specificity
Sensitivity and specificity
 
Ct lecture 20. survival analysis (part 2)
Ct lecture 20. survival analysis (part 2)Ct lecture 20. survival analysis (part 2)
Ct lecture 20. survival analysis (part 2)
 
Screening and diagnostic tests
Screening and diagnostic testsScreening and diagnostic tests
Screening and diagnostic tests
 
PMartinez - Literature Review
PMartinez - Literature ReviewPMartinez - Literature Review
PMartinez - Literature Review
 
Journal club-Determination of surgical priorities in appendicitis
Journal club-Determination of surgical priorities in appendicitisJournal club-Determination of surgical priorities in appendicitis
Journal club-Determination of surgical priorities in appendicitis
 
What is survival analysis, and when should I use it?
What is survival analysis, and when should I use it?What is survival analysis, and when should I use it?
What is survival analysis, and when should I use it?
 
Jc
JcJc
Jc
 
The values of clinical practice - Jordi Varela
The values of clinical practice - Jordi VarelaThe values of clinical practice - Jordi Varela
The values of clinical practice - Jordi Varela
 
Research on ADR in in-patients using Naronji's and who scale: A basic necessi...
Research on ADR in in-patients using Naronji's and who scale: A basic necessi...Research on ADR in in-patients using Naronji's and who scale: A basic necessi...
Research on ADR in in-patients using Naronji's and who scale: A basic necessi...
 

Similar to Proposal of a tool for the assessment of the quality of Gaucher disease clinical management.

Home enzymatic therapy administration for gaucher disease in spain
Home enzymatic therapy administration for gaucher disease in spainHome enzymatic therapy administration for gaucher disease in spain
Home enzymatic therapy administration for gaucher disease in spain
Vicente Giner Galvañ
 
Home enzymatic therapy administration program for lysosomal diseases in Spain...
Home enzymatic therapy administration program for lysosomal diseases in Spain...Home enzymatic therapy administration program for lysosomal diseases in Spain...
Home enzymatic therapy administration program for lysosomal diseases in Spain...
Vicente Giner Galvañ
 
10. SOP of QGPs.pptx
10. SOP of QGPs.pptx10. SOP of QGPs.pptx
10. SOP of QGPs.pptx
TunTunWin34
 
Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...
Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...
Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...
Prof. Eric Raymond Oncologie Medicale
 
vancouver style of reference
vancouver style of referencevancouver style of reference
vancouver style of reference
Raghu Prasada
 
(Student Name)Miami Regional UniversityDate of EncounterP
(Student Name)Miami Regional UniversityDate of EncounterP(Student Name)Miami Regional UniversityDate of EncounterP
(Student Name)Miami Regional UniversityDate of EncounterP
MoseStaton39
 
(Student Name)Miami Regional UniversityDate of EncounterP
(Student Name)Miami Regional UniversityDate of EncounterP(Student Name)Miami Regional UniversityDate of EncounterP
(Student Name)Miami Regional UniversityDate of EncounterP
SilvaGraf83
 
Integrative Telerehabilitation Strategy after Acute Coronary Syndrome
Integrative Telerehabilitation Strategy after Acute Coronary SyndromeIntegrative Telerehabilitation Strategy after Acute Coronary Syndrome
Integrative Telerehabilitation Strategy after Acute Coronary Syndrome
Ignacio Basagoiti
 
RAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMRAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUM
Kanhu Charan
 
Dr. Hoang Tuan - CLI102751EN-AP_2024_APAC_Vbeam Study Summary PWS V_240227_09...
Dr. Hoang Tuan - CLI102751EN-AP_2024_APAC_Vbeam Study Summary PWS V_240227_09...Dr. Hoang Tuan - CLI102751EN-AP_2024_APAC_Vbeam Study Summary PWS V_240227_09...
Dr. Hoang Tuan - CLI102751EN-AP_2024_APAC_Vbeam Study Summary PWS V_240227_09...
Vinson Co., Ltd
 
Journal club 1
Journal club 1Journal club 1
Journal club 1
Bhargav Kiran
 
Austin Aging Research
Austin Aging Research Austin Aging Research
Austin Aging Research
Austin Publishing Group
 
Home Telehealth for COPD Patients in Spain - ATA conference Austin ePoster (A...
Home Telehealth for COPD Patients in Spain - ATA conference Austin ePoster (A...Home Telehealth for COPD Patients in Spain - ATA conference Austin ePoster (A...
Home Telehealth for COPD Patients in Spain - ATA conference Austin ePoster (A...
Ofer Atzmon
 
091110 Kondrup IHF Rio
091110 Kondrup IHF Rio091110 Kondrup IHF Rio
091110 Kondrup IHF Rio
Jens Kondrup
 
Journal club 1
Journal club 1Journal club 1
Journal club 1
Bhargav Kiran
 
The effect of vitamin D add-on therapy on the improvement of.pdf
The effect of vitamin D add-on therapy on the improvement of.pdfThe effect of vitamin D add-on therapy on the improvement of.pdf
The effect of vitamin D add-on therapy on the improvement of.pdf
FinnyOktaria
 
Qualitative evaluation of the Home Therapy administration of enzymatic trea...
Qualitative evaluation of the Home Therapy administration  	of enzymatic trea...Qualitative evaluation of the Home Therapy administration  	of enzymatic trea...
Qualitative evaluation of the Home Therapy administration of enzymatic trea...
Vicente Giner Galvañ
 
Xerostomia level
Xerostomia levelXerostomia level
Xerostomia level
Andreas Ronald
 
3 dimensions of care for diabetes June 2015
3 dimensions of care for diabetes June 20153 dimensions of care for diabetes June 2015
3 dimensions of care for diabetes June 2015
NHS Improving Quality
 
NET - Kennecke
NET - KenneckeNET - Kennecke

Similar to Proposal of a tool for the assessment of the quality of Gaucher disease clinical management. (20)

Home enzymatic therapy administration for gaucher disease in spain
Home enzymatic therapy administration for gaucher disease in spainHome enzymatic therapy administration for gaucher disease in spain
Home enzymatic therapy administration for gaucher disease in spain
 
Home enzymatic therapy administration program for lysosomal diseases in Spain...
Home enzymatic therapy administration program for lysosomal diseases in Spain...Home enzymatic therapy administration program for lysosomal diseases in Spain...
Home enzymatic therapy administration program for lysosomal diseases in Spain...
 
10. SOP of QGPs.pptx
10. SOP of QGPs.pptx10. SOP of QGPs.pptx
10. SOP of QGPs.pptx
 
Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...
Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...
Tolerability and Activity of Second-Line Tepotinib, a Potent and Highly Selec...
 
vancouver style of reference
vancouver style of referencevancouver style of reference
vancouver style of reference
 
(Student Name)Miami Regional UniversityDate of EncounterP
(Student Name)Miami Regional UniversityDate of EncounterP(Student Name)Miami Regional UniversityDate of EncounterP
(Student Name)Miami Regional UniversityDate of EncounterP
 
(Student Name)Miami Regional UniversityDate of EncounterP
(Student Name)Miami Regional UniversityDate of EncounterP(Student Name)Miami Regional UniversityDate of EncounterP
(Student Name)Miami Regional UniversityDate of EncounterP
 
Integrative Telerehabilitation Strategy after Acute Coronary Syndrome
Integrative Telerehabilitation Strategy after Acute Coronary SyndromeIntegrative Telerehabilitation Strategy after Acute Coronary Syndrome
Integrative Telerehabilitation Strategy after Acute Coronary Syndrome
 
RAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMRAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUM
 
Dr. Hoang Tuan - CLI102751EN-AP_2024_APAC_Vbeam Study Summary PWS V_240227_09...
Dr. Hoang Tuan - CLI102751EN-AP_2024_APAC_Vbeam Study Summary PWS V_240227_09...Dr. Hoang Tuan - CLI102751EN-AP_2024_APAC_Vbeam Study Summary PWS V_240227_09...
Dr. Hoang Tuan - CLI102751EN-AP_2024_APAC_Vbeam Study Summary PWS V_240227_09...
 
Journal club 1
Journal club 1Journal club 1
Journal club 1
 
Austin Aging Research
Austin Aging Research Austin Aging Research
Austin Aging Research
 
Home Telehealth for COPD Patients in Spain - ATA conference Austin ePoster (A...
Home Telehealth for COPD Patients in Spain - ATA conference Austin ePoster (A...Home Telehealth for COPD Patients in Spain - ATA conference Austin ePoster (A...
Home Telehealth for COPD Patients in Spain - ATA conference Austin ePoster (A...
 
091110 Kondrup IHF Rio
091110 Kondrup IHF Rio091110 Kondrup IHF Rio
091110 Kondrup IHF Rio
 
Journal club 1
Journal club 1Journal club 1
Journal club 1
 
The effect of vitamin D add-on therapy on the improvement of.pdf
The effect of vitamin D add-on therapy on the improvement of.pdfThe effect of vitamin D add-on therapy on the improvement of.pdf
The effect of vitamin D add-on therapy on the improvement of.pdf
 
Qualitative evaluation of the Home Therapy administration of enzymatic trea...
Qualitative evaluation of the Home Therapy administration  	of enzymatic trea...Qualitative evaluation of the Home Therapy administration  	of enzymatic trea...
Qualitative evaluation of the Home Therapy administration of enzymatic trea...
 
Xerostomia level
Xerostomia levelXerostomia level
Xerostomia level
 
3 dimensions of care for diabetes June 2015
3 dimensions of care for diabetes June 20153 dimensions of care for diabetes June 2015
3 dimensions of care for diabetes June 2015
 
NET - Kennecke
NET - KenneckeNET - Kennecke
NET - Kennecke
 

More from javikin84

Juntos Hacia la Eliminación de la Hepatitis C
Juntos Hacia la Eliminación de la Hepatitis CJuntos Hacia la Eliminación de la Hepatitis C
Juntos Hacia la Eliminación de la Hepatitis C
javikin84
 
Consenso de recomendaciones para el diagnóstico precoz, la prevención y la at...
Consenso de recomendaciones para el diagnóstico precoz, la prevención y la at...Consenso de recomendaciones para el diagnóstico precoz, la prevención y la at...
Consenso de recomendaciones para el diagnóstico precoz, la prevención y la at...
javikin84
 
Congreso Autonómico SEMERGEN CV (Alicante 3 y 4 de Marzo 2017)
Congreso Autonómico SEMERGEN CV (Alicante 3 y 4 de Marzo 2017)Congreso Autonómico SEMERGEN CV (Alicante 3 y 4 de Marzo 2017)
Congreso Autonómico SEMERGEN CV (Alicante 3 y 4 de Marzo 2017)
javikin84
 
Congreso SEMERGEN Alicante
Congreso SEMERGEN AlicanteCongreso SEMERGEN Alicante
Congreso SEMERGEN Alicante
javikin84
 
LOS CSUR DE ERRORES CONGÉNITOS DE METABOLISMO DE ADULTOS. APLICABILIDAD CLÍNI...
LOS CSUR DE ERRORES CONGÉNITOS DE METABOLISMO DE ADULTOS. APLICABILIDAD CLÍNI...LOS CSUR DE ERRORES CONGÉNITOS DE METABOLISMO DE ADULTOS. APLICABILIDAD CLÍNI...
LOS CSUR DE ERRORES CONGÉNITOS DE METABOLISMO DE ADULTOS. APLICABILIDAD CLÍNI...
javikin84
 
Jornadas Residentes SEMERGEN CV. 11 y 12 de Noviembre de 2016. Calpe
Jornadas Residentes SEMERGEN CV. 11 y 12 de Noviembre de 2016. Calpe Jornadas Residentes SEMERGEN CV. 11 y 12 de Noviembre de 2016. Calpe
Jornadas Residentes SEMERGEN CV. 11 y 12 de Noviembre de 2016. Calpe
javikin84
 
Talleres de actualización en Medicina de Familia
Talleres de actualización en Medicina de FamiliaTalleres de actualización en Medicina de Familia
Talleres de actualización en Medicina de Familia
javikin84
 
Talleres de actualización en Medicina de Familia
Talleres de actualización en Medicina de FamiliaTalleres de actualización en Medicina de Familia
Talleres de actualización en Medicina de Familia
javikin84
 
SEMERGEN Taller Ecografía Músculo Esquelética
SEMERGEN Taller Ecografía Músculo EsqueléticaSEMERGEN Taller Ecografía Músculo Esquelética
SEMERGEN Taller Ecografía Músculo Esquelética
javikin84
 
5a JORNADA DE ACTUALIZACIÓN EN VACUNAS HOSPITAL MALVARROSA
5a JORNADA DE ACTUALIZACIÓN EN VACUNAS   HOSPITAL MALVARROSA5a JORNADA DE ACTUALIZACIÓN EN VACUNAS   HOSPITAL MALVARROSA
5a JORNADA DE ACTUALIZACIÓN EN VACUNAS HOSPITAL MALVARROSA
javikin84
 
Curso Intensivo Preparación de Oposiciones MÉDICOS DE ATENCIÓN PRIMARIA SEMERGEN
Curso Intensivo Preparación de Oposiciones MÉDICOS DE ATENCIÓN PRIMARIA SEMERGENCurso Intensivo Preparación de Oposiciones MÉDICOS DE ATENCIÓN PRIMARIA SEMERGEN
Curso Intensivo Preparación de Oposiciones MÉDICOS DE ATENCIÓN PRIMARIA SEMERGEN
javikin84
 
Taller ecografía SEMERGEN
Taller ecografía SEMERGENTaller ecografía SEMERGEN
Taller ecografía SEMERGEN
javikin84
 
Guía práctica de indicadores de calidad asistencial en la enfermedad de Gaucher
Guía práctica de indicadores de calidad asistencial en la enfermedad de GaucherGuía práctica de indicadores de calidad asistencial en la enfermedad de Gaucher
Guía práctica de indicadores de calidad asistencial en la enfermedad de Gaucher
javikin84
 
Día Enfermedades Minoritarias. Valencia 29 de Febrero 2016
Día Enfermedades Minoritarias. Valencia 29 de Febrero 2016Día Enfermedades Minoritarias. Valencia 29 de Febrero 2016
Día Enfermedades Minoritarias. Valencia 29 de Febrero 2016
javikin84
 
TVP un diagnostico ecografico
TVP un diagnostico ecograficoTVP un diagnostico ecografico
TVP un diagnostico ecografico
javikin84
 
Vacunación en el viajero
Vacunación en el viajeroVacunación en el viajero
Vacunación en el viajero
javikin84
 

More from javikin84 (16)

Juntos Hacia la Eliminación de la Hepatitis C
Juntos Hacia la Eliminación de la Hepatitis CJuntos Hacia la Eliminación de la Hepatitis C
Juntos Hacia la Eliminación de la Hepatitis C
 
Consenso de recomendaciones para el diagnóstico precoz, la prevención y la at...
Consenso de recomendaciones para el diagnóstico precoz, la prevención y la at...Consenso de recomendaciones para el diagnóstico precoz, la prevención y la at...
Consenso de recomendaciones para el diagnóstico precoz, la prevención y la at...
 
Congreso Autonómico SEMERGEN CV (Alicante 3 y 4 de Marzo 2017)
Congreso Autonómico SEMERGEN CV (Alicante 3 y 4 de Marzo 2017)Congreso Autonómico SEMERGEN CV (Alicante 3 y 4 de Marzo 2017)
Congreso Autonómico SEMERGEN CV (Alicante 3 y 4 de Marzo 2017)
 
Congreso SEMERGEN Alicante
Congreso SEMERGEN AlicanteCongreso SEMERGEN Alicante
Congreso SEMERGEN Alicante
 
LOS CSUR DE ERRORES CONGÉNITOS DE METABOLISMO DE ADULTOS. APLICABILIDAD CLÍNI...
LOS CSUR DE ERRORES CONGÉNITOS DE METABOLISMO DE ADULTOS. APLICABILIDAD CLÍNI...LOS CSUR DE ERRORES CONGÉNITOS DE METABOLISMO DE ADULTOS. APLICABILIDAD CLÍNI...
LOS CSUR DE ERRORES CONGÉNITOS DE METABOLISMO DE ADULTOS. APLICABILIDAD CLÍNI...
 
Jornadas Residentes SEMERGEN CV. 11 y 12 de Noviembre de 2016. Calpe
Jornadas Residentes SEMERGEN CV. 11 y 12 de Noviembre de 2016. Calpe Jornadas Residentes SEMERGEN CV. 11 y 12 de Noviembre de 2016. Calpe
Jornadas Residentes SEMERGEN CV. 11 y 12 de Noviembre de 2016. Calpe
 
Talleres de actualización en Medicina de Familia
Talleres de actualización en Medicina de FamiliaTalleres de actualización en Medicina de Familia
Talleres de actualización en Medicina de Familia
 
Talleres de actualización en Medicina de Familia
Talleres de actualización en Medicina de FamiliaTalleres de actualización en Medicina de Familia
Talleres de actualización en Medicina de Familia
 
SEMERGEN Taller Ecografía Músculo Esquelética
SEMERGEN Taller Ecografía Músculo EsqueléticaSEMERGEN Taller Ecografía Músculo Esquelética
SEMERGEN Taller Ecografía Músculo Esquelética
 
5a JORNADA DE ACTUALIZACIÓN EN VACUNAS HOSPITAL MALVARROSA
5a JORNADA DE ACTUALIZACIÓN EN VACUNAS   HOSPITAL MALVARROSA5a JORNADA DE ACTUALIZACIÓN EN VACUNAS   HOSPITAL MALVARROSA
5a JORNADA DE ACTUALIZACIÓN EN VACUNAS HOSPITAL MALVARROSA
 
Curso Intensivo Preparación de Oposiciones MÉDICOS DE ATENCIÓN PRIMARIA SEMERGEN
Curso Intensivo Preparación de Oposiciones MÉDICOS DE ATENCIÓN PRIMARIA SEMERGENCurso Intensivo Preparación de Oposiciones MÉDICOS DE ATENCIÓN PRIMARIA SEMERGEN
Curso Intensivo Preparación de Oposiciones MÉDICOS DE ATENCIÓN PRIMARIA SEMERGEN
 
Taller ecografía SEMERGEN
Taller ecografía SEMERGENTaller ecografía SEMERGEN
Taller ecografía SEMERGEN
 
Guía práctica de indicadores de calidad asistencial en la enfermedad de Gaucher
Guía práctica de indicadores de calidad asistencial en la enfermedad de GaucherGuía práctica de indicadores de calidad asistencial en la enfermedad de Gaucher
Guía práctica de indicadores de calidad asistencial en la enfermedad de Gaucher
 
Día Enfermedades Minoritarias. Valencia 29 de Febrero 2016
Día Enfermedades Minoritarias. Valencia 29 de Febrero 2016Día Enfermedades Minoritarias. Valencia 29 de Febrero 2016
Día Enfermedades Minoritarias. Valencia 29 de Febrero 2016
 
TVP un diagnostico ecografico
TVP un diagnostico ecograficoTVP un diagnostico ecografico
TVP un diagnostico ecografico
 
Vacunación en el viajero
Vacunación en el viajeroVacunación en el viajero
Vacunación en el viajero
 

Recently uploaded

Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
semualkaira
 
Nosodes in Homeopathy, Understanding the Basis and Applications.pptx
Nosodes in Homeopathy, Understanding the Basis and Applications.pptxNosodes in Homeopathy, Understanding the Basis and Applications.pptx
Nosodes in Homeopathy, Understanding the Basis and Applications.pptx
jeearu
 
11_Eclampsia and preeclampsia real.pptxf
11_Eclampsia and preeclampsia real.pptxf11_Eclampsia and preeclampsia real.pptxf
11_Eclampsia and preeclampsia real.pptxf
kkamaraansumana
 
Geriatric radiography.pptx Geriatric radiography.pptxGeriatric radiography.pptx
Geriatric radiography.pptx Geriatric radiography.pptxGeriatric radiography.pptxGeriatric radiography.pptx Geriatric radiography.pptxGeriatric radiography.pptx
Geriatric radiography.pptx Geriatric radiography.pptxGeriatric radiography.pptx
Dinesh Danny
 
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Anindya Das Adhikary
 
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in DohaAbortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
maishakhanam230
 
Clinical examination of- CRANIAL.- nerves
Clinical examination of- CRANIAL.- nervesClinical examination of- CRANIAL.- nerves
Clinical examination of- CRANIAL.- nerves
DrpoonamHealthclinic
 
2nd week of Human development .embryology
2nd week of Human development .embryology2nd week of Human development .embryology
2nd week of Human development .embryology
Mithilesh Chaurasia
 
Top 10 Habits for Longevity [Biohacker Summit 2024]
Top 10 Habits for Longevity [Biohacker Summit 2024]Top 10 Habits for Longevity [Biohacker Summit 2024]
Top 10 Habits for Longevity [Biohacker Summit 2024]
Olli Sovijärvi
 
FUNCTIONAL DYSPEPSIA by Dr. Maryam Iqbal
FUNCTIONAL DYSPEPSIA by Dr. Maryam IqbalFUNCTIONAL DYSPEPSIA by Dr. Maryam Iqbal
FUNCTIONAL DYSPEPSIA by Dr. Maryam Iqbal
Zain Umar
 
Handbook of Dental anatomy (practical part)
Handbook of Dental anatomy (practical part)Handbook of Dental anatomy (practical part)
Handbook of Dental anatomy (practical part)
MuhammedMNasser
 
Perforation.pptx
Perforation.pptxPerforation.pptx
Perforation.pptx
Nandish Sannaiah
 
anthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology depanthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology dep
sapnasirswal
 
lessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical educationlessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical education
DrJALAGAMTHIRUPATHIR
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
drebrahiim
 
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptxExploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
FFragrant
 
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.GawadHemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
NephroTube - Dr.Gawad
 
AGARICUS MUSCARIUS.pptx Keynotes by H.C. Allen
AGARICUS MUSCARIUS.pptx  Keynotes by H.C. AllenAGARICUS MUSCARIUS.pptx  Keynotes by H.C. Allen
AGARICUS MUSCARIUS.pptx Keynotes by H.C. Allen
DR.P.S SUDHAKAR
 
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Dr.Nishant Janu
 
Text Book of Nursing Concepts - Fundamental of Nursing
Text Book of Nursing Concepts - Fundamental of NursingText Book of Nursing Concepts - Fundamental of Nursing
Text Book of Nursing Concepts - Fundamental of Nursing
BP KOIRALA INSTITUTE OF HELATH SCIENCS,, NEPAL
 

Recently uploaded (20)

Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
 
Nosodes in Homeopathy, Understanding the Basis and Applications.pptx
Nosodes in Homeopathy, Understanding the Basis and Applications.pptxNosodes in Homeopathy, Understanding the Basis and Applications.pptx
Nosodes in Homeopathy, Understanding the Basis and Applications.pptx
 
11_Eclampsia and preeclampsia real.pptxf
11_Eclampsia and preeclampsia real.pptxf11_Eclampsia and preeclampsia real.pptxf
11_Eclampsia and preeclampsia real.pptxf
 
Geriatric radiography.pptx Geriatric radiography.pptxGeriatric radiography.pptx
Geriatric radiography.pptx Geriatric radiography.pptxGeriatric radiography.pptxGeriatric radiography.pptx Geriatric radiography.pptxGeriatric radiography.pptx
Geriatric radiography.pptx Geriatric radiography.pptxGeriatric radiography.pptx
 
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
 
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in DohaAbortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
Abortion pills for sale in Qatar(+919707208804)Buy Cytotec tablet in Doha
 
Clinical examination of- CRANIAL.- nerves
Clinical examination of- CRANIAL.- nervesClinical examination of- CRANIAL.- nerves
Clinical examination of- CRANIAL.- nerves
 
2nd week of Human development .embryology
2nd week of Human development .embryology2nd week of Human development .embryology
2nd week of Human development .embryology
 
Top 10 Habits for Longevity [Biohacker Summit 2024]
Top 10 Habits for Longevity [Biohacker Summit 2024]Top 10 Habits for Longevity [Biohacker Summit 2024]
Top 10 Habits for Longevity [Biohacker Summit 2024]
 
FUNCTIONAL DYSPEPSIA by Dr. Maryam Iqbal
FUNCTIONAL DYSPEPSIA by Dr. Maryam IqbalFUNCTIONAL DYSPEPSIA by Dr. Maryam Iqbal
FUNCTIONAL DYSPEPSIA by Dr. Maryam Iqbal
 
Handbook of Dental anatomy (practical part)
Handbook of Dental anatomy (practical part)Handbook of Dental anatomy (practical part)
Handbook of Dental anatomy (practical part)
 
Perforation.pptx
Perforation.pptxPerforation.pptx
Perforation.pptx
 
anthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology depanthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology dep
 
lessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical educationlessonplan JTR.pptx For medical education
lessonplan JTR.pptx For medical education
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
 
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptxExploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
 
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.GawadHemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 3 - Dr.Gawad
 
AGARICUS MUSCARIUS.pptx Keynotes by H.C. Allen
AGARICUS MUSCARIUS.pptx  Keynotes by H.C. AllenAGARICUS MUSCARIUS.pptx  Keynotes by H.C. Allen
AGARICUS MUSCARIUS.pptx Keynotes by H.C. Allen
 
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
Gestational Trophoblastic Disease( GTD)- Molar pregnancy, Gestational Trophob...
 
Text Book of Nursing Concepts - Fundamental of Nursing
Text Book of Nursing Concepts - Fundamental of NursingText Book of Nursing Concepts - Fundamental of Nursing
Text Book of Nursing Concepts - Fundamental of Nursing
 

Proposal of a tool for the assessment of the quality of Gaucher disease clinical management.

  • 1. 107. Proposal of a tool for the assessment of the quality of Gaucher disease clinical management. *Giner V1 , Fernández MA2 , Villarrubia J3 , Bureo JC4 , Fernández JJ5 , Núñez R6 , Grande M7 , Llorente C7 , Zoni AC8 , Arenas CA9 , Vicente D1 , Sanz J1 . 1 Rare Diseases Unit. Department of General Internal Medicine. Hospital Mare de Déu dels Lliris. Alcoy. Spain. 2 Department of Hematology. Hospital Virgen del Puerto. Plasencia (Cáceres).Spain. 3 Department of Hematology. Hospital Universitario Ramón y Cajal. Madrid. Spain. 4 Department of General Internal Medicine. Hospital Infanta Cristina. Badajoz. Spain. 5 Department of General Internal Medicine. Hospital do Meixoeiro. Vigo. Spain. 6 Unit of Hemophilia. Department of Hematology. Hospital Universitario Virgen del Rocío. Sevilla. Spain. 7 Department of Preventive Medicine and Quality of Care. Hospital General Universitario Gregorio Marañón. SERMAS. Madrid. Spain. 8 Epidemiology Area. Subdirection for Health Promotion and Prevention. Consejería de Salud de la Comunidad de Madrid. Madrid. Spain. 9 Sociedad Española de Directivos de Salud (SEDISA). *Presenting and corresponding author: giner_vicgal@gva.es IntroductionIntroduction MethodologyMethodology Internal Medicine Department Rare Diseases Unit Alcoi (Alicante). Spain. To avoid unjustified clinical variation in the way we manage our patinets and to assure it is being done in the best way, it is necessary tools for the evaluation of the quality of our work. It is specially noteworthy in rare diseases due to the scarce amount of clear and definite evidence we have. To create a tool for the evalution of the assistance given to GD patients as the first step to improve our assisstance. Phase 1 Objetive: Identification and analysis of existing publications about quality in GD management. Methodology: Review of the published evidence in Medline (PubMed)© , Embase© and Cochrane© databases according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology until october 2013. Phase 2 Objetive: First proposal of quality criteria for 3 clinical scenarios: Diagnosis, Treatment and Follow-up. Methodology: Creation of an expert group with seven national experts on GD. Initial proposal for quality criteria after evaluation and adaptation to spanish clinical practice. As illustrated in Figure 1, the project was developed in four consecutive phases between 2013 and 2016: Phase 3 Objetive: General consensus for the election of significant quality indicators. Methodology: Identification of national physicians with expertise in the management of GD. Consensuated evaluation of proposed quality criteria by 31 national treating GD patients in two Delphi rounds. In each round the panelists evaluated each proposal applying a 9 points Likert scale. Phase 4 Objetive: Final manuscript for clinical aplication. Methodology: Creation of a work sheet for each quality indicator according to Sociedad Española de Calidad Asistencial (SECA) (Spanish Society of Assitential Quality) 2012 protocol for the Spanish Public Health System hospitals. ResultsResults Phase 1 Phase 2 Phase 3 Phase 4 ScenarioScenario Quality parameterQuality parameter CalculationCalculation ObjectiveObjective Diagnosis (D) D1. Anamnesis and physical exploration GD patients with D1/All GD patients x 100 100% D2. Basic general analytical study GD patients with D2/All GD patients x 100 100% D3. Glucocerebrosidase activity GD patients with D3/All GD patients x 100 100% D4. Genetic study GD patients with D4/All GD patients x 100 100% D5. Biomarkers GD patients with D5/All GD patients x 100 100% D6. Bone disease evaluation GD patients with D6/All GD patients x 100 100% D7. Organomegaly evaluation GD patients with D7/All GD patients x 100 100% D8. Global severity evaluation GD patients with D8/All GD patients x 100 100% D9. Exhaustive familial story GD patients with D9/All GD patients x 100 100% D10. Familial screening GD patients with D10/All GD patients x 100 100% Treatment (T)ERT: Enzyme replacement Therapy SRT: Substracte reduction Therapy T1. Specific treatment: ERT GD patients with T1/All GD patients x 100 T1.1 and T1.2 100%, T1.3 50%, T1.4 0% T2. Specific treatment: SRT GD patients with T2/All GD patients x 100 100% T3. Therap. objective: Anemia GD patients with T3/All GD patients x 100 100% T4. Therap. objective: Thrombopenia GD patients with T4/All GD patients x 100 T4.1, T4.2, T4.3, T4.4, T4.5 100% T5. Therap. objective: Hepatomegaly GD patients with T5/All GD patients x 100 T5.1 ≥20 %, T5.2 ≥30 %. T6. Therap. objective: Splenomegaly GD patients with T6/All GD patients x 100 T6.1 ≥30 %, T6.2 ≥60 %. T7. Therap. objective: Bone GD patients with T7/All GD patients x 100 T7.1 ≥20%, T7.2 ≥50%, T7.3 ≥30%. Follow-up (F) F1. Continuos and planned follow-up GD patients with T7/All GD patients x 100 F1.1, F1.2, F1.3 100% F2. No reached objectives GD patients with T7/All GD patients x 100 100% ConclusionsConclusions Figure 1. Methodological phases in the confection of the final document entitled “Guía práctica de indicadores de calidad asistencial en la enfermedad de Gaucher” (“Practical guideline of assistential quality indicators in Gaucher disease”). This project has been supported by Shire Pharmaceuticals Iberica© ObjectiveObjective Although the process of quality is essential to improve health care, the presented is the only reported specific tool to assess quality of actual GD clinical management. Because of very scarce bibliographic evidence and high level of consensuated decisions, probably a specific document for each Health system is necessary. The simplicity of the proposed system could facilitate its application as a way to improve and standarize clinical management of GD patients as a continuous improvement process.